Emeis Stock: Significant Drop of 6.65% at Midday

Financial Performance Exceeds Expectations

The health and social care group Emeis revealed on Tuesday its 2025 financial results that surpassed its own targets. EBITDAR increased by 19.2% on a like-for-like basis, while the financial leverage ratio significantly reduced from 19.5x to 10.0x within a year. This substantial debt reduction accompanies an overall improvement in the group's operational performance. Despite these encouraging fundamentals, the stock strongly declined this Thursday. However, the stock's performance over the year remains remarkable, with an increase of nearly 68%. Today's correction brings the price close to its 20-day moving average of 14.34 euros, suggesting a return to valuation levels closer to the short-term trend after a prolonged upward movement.

Recent Analyst Upgrades

On the eve of this decline, the bank Oddo BHF revised its price target on Emeis upwards, from 15.50 to 16.50 euros, while maintaining an 'outperform' rating. At the current price of 14.46 euros, this new target indicates a potential revaluation of about 14%. Technically, the stock is now trading between a support threshold identified at 13.49 euros and a resistance at 15.49 euros, which exactly corresponded to the previous day's closing price. The RSI, at 68, remains close to the overbought zone without crossing it, indicating that the bullish momentum is still intact over the past few weeks despite today's drop. The 50-day moving average, positioned at 14.01 euros, continues to provide intermediate support for the medium-term trajectory of the stock.